This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock About Immuron Stock (NASDAQ:IMRN) 30 days 90 days 365 days Advanced Chart Get Immuron alerts:Sign Up Key Stats Today's Range$1.85▼$2.1350-Day Range$4.80▼$5.6152-Week Range$1.60▼$2.87Volume12,391 shsAverage Volume9,605 shsMarket Capitalization$11.21 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.Read More… Immuron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreIMRN MarketRank™: Immuron scored higher than 24% of companies evaluated by MarketBeat, and ranked 783rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmuron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmuron has received no research coverage in the past 90 days.Read more about Immuron's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immuron are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.Price to Book Value per Share RatioImmuron has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently increased by 58.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuron does not currently pay a dividend.Dividend GrowthImmuron does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.31% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently increased by 58.33%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Immuron this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.01% of the stock of Immuron is held by insiders.Percentage Held by InstitutionsOnly 0.12% of the stock of Immuron is held by institutions.Read more about Immuron's insider trading history. Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRN Stock News HeadlinesImmuron reports record Travelan salesApril 12, 2025 | uk.investing.comImmuron Limited Announces New Share IssuanceApril 11, 2025 | tipranks.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.May 3, 2025 | Brownstone Research (Ad)Immuron Limited Announces New Securities IssuanceApril 11, 2025 | tipranks.comImmuron Limited Announces Cessation of Performance RightsApril 11, 2025 | tipranks.comImmuron Travelan® highest sales in historyApril 10, 2025 | globenewswire.comImmuron Limited Achieves Record Sales with Travelan®April 9, 2025 | tipranks.comImmuron partners with Calmino to distribute ProIBS in Australia, New ZealandMarch 6, 2025 | markets.businessinsider.comSee More Headlines IMRN Stock Analysis - Frequently Asked Questions When did Immuron IPO? Immuron (IMRN) raised $6 million in an initial public offering (IPO) on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX). Company Calendar Today5/03/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRN CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+160.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio4.87 Sales & Book Value Annual Sales$3.21 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book1.32Miscellaneous Outstanding Shares5,840,000Free Float5,429,000Market Cap$11.21 million OptionableNot Optionable Beta1.38 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:IMRN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.